BEAM-302
Idiopathic Pulmonary Fibrosis · CRISPR Base Editing
Clinical trials
1
Mechanism
CRISPR Base Editing
Developer
Beam Therapeutics
Overview
BEAM-302 is an agent tracked by PF-Atlas in the context of idiopathic pulmonary fibrosis, acting via crispr base editing. It appears in 1 tracked IPF clinical trial.
BEAM-302 clinical trials
Explore related
Medical disclaimer. This page summarizes research about BEAM-302 for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.